KUSI was joined by Medical Oncologist Dr. Richard Schwab of US San Diego with more on the study.
Many women with early-stage breast cancer who would receive chemotherapy under current standards do not actually need it, according to a major global study that is expected to quickly change medical treatment.
He said: This is a remarkable and extremely promising result, but we need to see this effect repeated in other patients before giving hope of a new immunotherapy for incurable metastatic breast cancer. "The study showed that if you take the group as a whole, there is no difference in the risk of recurrence when you compare chemotherapy to no chemotherapy".
John Heymach, a professor at the University of Texas MD Anderson Cancer Center who was not involved in the Merck-funded study, described it as a "true milestone" and "a real important advance for patients".
The second study tested a form of immunotherapy against chemo, in the most common lung cancer worldwide, known as non-small-cell lung cancer.
With women hardest hit by migraine headaches, Swiss drugmaker Novartis is gearing up its marketing message to counteract sexism that it worries might become a barrier to adoption of its new medicine Aimovig. The results are similar for women under 50 with a score between 0 and 15.
The study is limited in some ways.
The New England Journal of Medicine published a study on Sunday that examined a popular genetic test that estimated cancer risk based on nearly two dozen genes linked with the recurrence of breast cancer, according to CNN.
The cancer in question is driven by hormones, has not spread to the lymph nodes and does not contain a protein called HER2. After surgery, one group got endocrine therapy only, while the other was treated with endocrine therapy plus chemotherapy.
"You have to balance risk versus benefit and if you can spare people the negative side effects that chemo brings along with the cost, that's big" ABC News' Chief Medical Editor Dr. Jennifer Ashton said on "Good Morning America".
The study did note that these findings may not apply to premenopausal women.
The study enrolled 10,273 women, of whom 9719 with follow-up data were included in the main analysis set; 6711 women (69%) had an intermediate recurrence score of 11-25, while 1619 (17%) had a low recurrence sore of 10 or less and 1389 (14%) had a recurrence score of 26 or higher.
Patients, aged 18 to 75, were randomly assigned to receive chemotherapy followed by hormonal therapy or hormone therapy alone. "I've been anxious for a long time about unnecessary treatment for cancer, and unnecessary side effects from chemotherapy".
"I think it's been well spent", Singer said of the stamp proceeds.
When Perkins received her experimental therapy just before Christmas 2014, she said she sensed the optimism of the National Cancer Institute researchers who devised this new approach to immunotherapy. "Now we know there's no need to give chemotherapy to those patients anymore", Mitchell said.
Harold Burstein, a breast cancer specialist at Dana-Farber Cancer Institute, said that in some ways the debate over de-escalation misses a larger issue. In fact several studies have shown that immunotherapy works well in some patients and tend to fail in many patients.
"Chemotherapy is no Shangri-La", Brawley said.